Skip to main content

Advertisement

SpringerLink
Log in

Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity

  • Original Article
  • Published:
Immunologic Research Aims and scope Submit manuscript

Abstract

Adenosine deaminase (ADA) has been found to be involved in autoimmune disease progression. To assess the potential application of serum ADA activity in diagnosing systemic lupus erythematosus (SLE) and evaluating SLE disease activity, we investigated the serum ADA activity of 120 SLE patients and 120 healthy controls in the present study. The results showed that serum ADA activity in SLE patients was significantly increased (median (IQR) = 14 (11–19) U/L) compared with that in healthy controls (median (IQR) = 8 (7–10) U/L). Based on a receiver operating characteristic curve analysis, the optimal cut-off value for using serum ADA activity to diagnose SLE patients was 10.5 U/L (specificity, 84.2%; sensitivity, 78.3%). The diagnostic performance of serum ADA activity for SLE patients was better than that of other conventional haematology markers. Moreover, serum ADA activity displayed an increasing trend with increasing SLE disease activity. Spearman’s correlation analysis showed that serum ADA activity was positively correlated with SLE disease activity. These findings suggest that serum ADA activity could be a diagnostic marker for SLE; moreover, measuring serum ADA activity may be helpful for evaluating and monitoring the disease activity of SLE patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25(1):33–9. https://doi.org/10.1016/j.it.2003.11.003.

    Article  CAS  PubMed  Google Scholar 

  2. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7(9):759–70. https://doi.org/10.1038/nrd2638.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Franco R, Valenzuela A, Lluis C, Blanco J. Enzymatic and extraenzymatic role of ecto-adenosine deaminase in lymphocytes. Immunol Rev. 1998;161(1):27–42. https://doi.org/10.1111/j.1600-065X.1998.tb01569.x.

    Article  CAS  PubMed  Google Scholar 

  4. Whitmore KV, Gaspar HB. Adenosine deaminase deficiency—more than just an immunodeficiency. Front Immunol. 2016;7:314. https://doi.org/10.3389/fimmu.2016.00314.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312(7):729–38. https://doi.org/10.1001/jama.2014.9132.

  6. Cicalese MP, Ferrua F, Castagnaro L, Pajno R, Barzaghi F, Giannelli S, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. 2016;128(1):45–54. https://doi.org/10.1182/blood-2016-01-688226.

  7. Ferrua F, Brigida I, Aiuti A. Update on gene therapy for adenosine deaminase-deficient severe combined immunodeficiency. Blood. 2010;10(6):551–6. https://doi.org/10.1182/blood-2016-01-688226.

    CAS  Google Scholar 

  8. Sauer AV, Morbach H, Brigida I, Ng YS, Aiuti A, Meffre E. Defective B cell tolerance in adenosine deaminase deficiency is corrected by gene therapy. J Clin Investig. 2012a;122(6):2141–52. https://doi.org/10.1172/jci61788.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Sauer AV, Brigida I, Carriglio N, Hernandez RJ, Scaramuzza S, Clavenna D, et al. Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID. Blood. 2012b;119(6):1428–39. https://doi.org/10.1182/blood-2011-07-366781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Sauer AV, Brigida I, Carriglio N, Aiuti A. Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency. Front Immunol. 2012c;3:265. https://doi.org/10.3389/fimmu.2012.00265.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vinapamula KS, Pemmaraju SV, Bhattaram SK, Bitla AR, Manohar SM. Serum adenosine deaminase as inflammatory marker in rheumatoid arthritis. J Clin Diagn Res: JCDR. 2015;9(9):Bc08–10. https://doi.org/10.7860/jcdr/2015/14296.6483.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Xun C, Zhao Y, Hu ZJ. Potential role of adenosine deaminase in the diagnosis of adult-onset Still’s disease. Rheumatol Int. 2013;33(5):1255–8. https://doi.org/10.1007/s00296-012-2532-z.

    Article  CAS  PubMed  Google Scholar 

  13. Taysi S, Polat MF, Sari RA, Bakan E. Serum adenosine deaminase and cytidine deaminase activities in patients with systemic lupus erythematosus. Clin Chem Lab Med. 2002;40(5):493–5. https://doi.org/10.1515/cclm.2002.085.

    Article  CAS  PubMed  Google Scholar 

  14. Nalesnik M, Nikolic JM, Jandric S. Adenosine deaminase and C-reactive protein in diagnosing and monitoring of rheumatoid arthritis. Medicinski Glasnik: Off Publ Med Assoc Zenica-Doboj Canton, Bosnia and Herzegovina. 2011;8(1):163–8.

    Google Scholar 

  15. Saghiri R, Ghashghai N, Movaseghi S, Poursharifi P, Jalilfar S, Bidhendi MA, et al. Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern. Rheumatol Int. 2012;32(6):1633–8. https://doi.org/10.1007/s00296-011-1836-8.

    Article  CAS  PubMed  Google Scholar 

  16. Hitoglou S, Hatzistilianou M, Gougoustamou D, Athanassiadou F, Kotsis A, Catriu D. Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol. 2001;20(6):411–6.

    Article  CAS  PubMed  Google Scholar 

  17. Demir G, Borman P, Ayhan F, Ozgun T, Kaygisiz F, Yilmez G. Serum adenosine deaminase level is high but not related with disease activity parameters in patients with rheumatoid arthritis. Open Rheumatol J. 2014;8(1):24–8. https://doi.org/10.2174/1874312901408010024.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Zamani B, Jamali R, Jamali A. Serum adenosine deaminase may predict disease activity in rheumatoid arthritis. Rheumatol Int. 2012;32(7):1967–75. https://doi.org/10.1007/s00296-011-1912-0.

    Article  CAS  PubMed  Google Scholar 

  19. Wang D, Huang S, Yuan X, Liang J, Xu R, Yao G, et al. The regulation of the Treg/Th17 balance by mesenchymal stem cells in human systemic lupus erythematosus. Cell Mol Immunol. 2015;14(5):423–31. https://doi.org/10.1038/cmi.2015.89.

    Article  PubMed  Google Scholar 

  20. Ohl K, Tenbrock K. Regulatory T cells in systemic lupus erythematosus. Eur J Immunol. 2015;45(2):344–55. https://doi.org/10.1002/eji.201344280.

    Article  CAS  PubMed  Google Scholar 

  21. Mak A, Kow NY. Imbalance between endothelial damage and repair: a gateway to cardiovascular disease in systemic lupus erythematosus. Biomed Res Int. 2014;2014:178721–11. https://doi.org/10.1155/2014/178721.

    Article  PubMed  PubMed Central  Google Scholar 

  22. van den Berg L, Nossent H, Rekvig O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol. 2006;25(3):347–52. https://doi.org/10.1007/s10067-005-0047-7.

    Article  PubMed  Google Scholar 

  23. Chung L, Flyckt RL, Colon I, Shah AA, Druzin M, Chakravarty EF. Outcome of pregnancies complicated by systemic sclerosis and mixed connective tissue disease. Lupus. 2006;15(9):595–9. https://doi.org/10.1177/0961203306071915.

    Article  CAS  PubMed  Google Scholar 

  24. Forger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of anti-dsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;13(1):36–44. https://doi.org/10.1191/0961203304lu485oa.

    Article  CAS  PubMed  Google Scholar 

  25. Jolly M, Smaron M, Olsen Utset T, Ellman M. Are isolated antinucleolar antibodies a marker of scleroderma? J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2003;9(5):291–5. https://doi.org/10.1097/01.rhu.0000089790.80026.f4.

    Article  Google Scholar 

  26. van Venrooij WJ, Charles P, Maini RN. The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods. 1991;140(2):181–9. https://doi.org/10.1016/0022-1759(91)90369-Q.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by the National Natural Science Foundation of China (no. 81572974).

Author information

Author notes

  1. Z.G. and G.Z. contributed equally to this work.

Authors and Affiliations

  1. Department of Clinical Diagnosis, Tangdu Hospital, Fourth Military Medical University, Xinsi Road, Xi’an, Shanxi, 710038, China

    Zhao-wei Gao, Guan-hua Zhao, Zhe Zhang, Jing Huang, Zi-yue Li, Hui-zhong Zhang & Ke Dong

Authors
  1. Zhao-wei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guan-hua Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhe Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zi-yue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hui-zhong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ke Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Hui-zhong Zhang or Ke Dong.

Ethics declarations

This project was approved by the Ethics Committee of the Tangdu Hospital, Fourth Military Medical University. Ethical approval was obtained from the Ethics Committee of Tangdu Hospital, Fourth Military Medical University (TDLL-20151209), and informed consent was not required.

Conflict of interests

The authors declare that they have no conflict of interest.

Electronic supplementary material

ESM 1

(XLSX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gao, Zw., Zhao, Gh., Zhang, Z. et al. Serum adenosine deaminase activity is increased in systemic lupus erythematosus patients and correlated with disease activity. Immunol Res 66, 299–304 (2018). https://doi.org/10.1007/s12026-018-8984-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12026-018-8984-9

Keywords

Search

Navigation